Fig. 6

Residual inflammatory risk and potential therapeutic targets. Conceptual framework illustrating the role of residual inflammatory risk (RIR) in post-PCI care, integrating hsCRP assessment and potential downstream biomarkers (interleukin-1, interleukin-6) for comprehensive risk stratification and pharmacological targeting.